Management ChangeApr 28, 2026, 04:01 PM
CRDF Grants 400,000 Stock Options to New COO Dr. Aggarwal
AI Summary
Cardiff Oncology, Inc. announced the grant of non-qualified stock options to Dr. Aggarwal upon his appointment as Chief Operating Officer. The grant includes options to purchase 400,000 shares of common stock at an exercise price of $1.72 per share, the closing price on April 27, 2026. This inducement grant vests over four years, with 25% after 12 months and the remainder monthly over 36 months, contingent on continued employment.
Key Highlights
- Dr. Aggarwal appointed Chief Operating Officer of Cardiff Oncology.
- Granted non-qualified stock options for 400,000 shares.
- Exercise price of options is $1.72 per share.
- Options vest over four years, with 25% after 12 months.
- Grant date for the options was April 27, 2026.
Price Impact
More from CRDF